Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis
| Autor: | Yu Cao, Rongsheng Du, You Chen, Dongze Li, Xin Liu, Wei Zhang, Jiang Wu, Jing Yu, Zhiwei Zhao, Rui Zeng, Ying Liu, Zhi Zeng, Lizhi Zhao |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Clinical Biochemistry Coronary Disease 030204 cardiovascular system & hematology Biochemistry 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Humans Medicine Prospective cohort study business.industry Lipoprotein-associated phospholipase A2 Biochemistry (medical) Hazard ratio General Medicine Coronary heart disease Confidence interval 030104 developmental biology Increased risk Coronary heart disease review Meta-analysis 1-Alkyl-2-acetylglycerophosphocholine Esterase Cardiology lipids (amino acids peptides and proteins) business Biomarkers |
| Zdroj: | Clinica Chimica Acta. 465:22-29 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/j.cca.2016.12.006 |
| Popis: | Background Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of the meta-analysis was to investigate the association between Lp-PLA2 and prognosis of CHD. Methods PubMed and Embase were examined for prospective studies published before June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of adverse outcomes according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using generic inverse-variance and random-effect modeling. Results Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality. However, higher Lp-PLA2 activity or mass was independently associated with an increased risk of long-term cardiovascular events, with pooled HR for cardiovascular events of 1.55 (95% CI, 1.08–2.23; P = 0.018) and 1.62 (95% CI, 1.09–2.41; P = 0.017), respectively. The prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2. Conclusions Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect